Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics

Trial Profile

A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Cancer
  • Focus Pharmacokinetics
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 27 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top